Company research
ALNYLAM PHARMACEUTICALS, INC.
CIK 1178670Updated Nov 18, 2026
ALNY price & chart
Loading TradingView…
NASDAQ:ALNY on TradingView ↗About the company
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products include AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran), which are being developed and commercialized by Alnylam, and Leqvio® (inclisiran) and Qfitlia™ (fitusiran), which are being developed and commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable i…
In the news
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation ↗
Recent filings
4 filing
SCHEDULE 13G/A - filed by FMR LLC regarding ALNYLAM PHARMACEUTICALS, INC.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 4,851,662,000Source | 4,205,039,000Source | 3,839,073,000Source | 5,558,769,000Source | 4,566,019,000Source | 4,009,634,000Source | 4,213,811,000Source | 3,824,386,000Source | 4,966,331,000Source | 4,239,983,000Source | 3,829,880,000Source | 3,546,359,000Source |
| Property, Plant and Equipment, NetUSD | 501,754,000Source | 506,997,000Source | 525,591,000Source | 554,143,000Source | 499,791,000Source | 517,159,000Source | 498,684,000Source | 523,460,000Source | 513,147,000Source | 502,784,000Source | 526,057,000Source | 523,494,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,490,249,000Source | 1,099,920,000Source | 1,033,024,000Source | 1,708,318,000Source | 1,113,685,000Source | 968,492,000Source | 1,019,654,000Source | 681,879,000Source | 1,657,250,000Source | 966,428,000Source | 812,688,000Source | 866,394,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 964,768,000Source | 353,852,000Source | 325,445,000Source | 912,739,000Source | 567,112,000Source | 309,481,000Source | 418,035,000Source | 321,377,000Source | 777,567,000Source | 405,308,000Source | 327,787,000Source | 237,963,000Source |
| Inventory, NetUSD | 75,383,000Source | 75,987,000Source | 95,771,000Source | 97,110,000Source | 71,688,000Source | 83,981,000Source | 65,581,000Source | 93,988,000Source | 82,719,000Source | 78,509,000Source | 89,146,000Source | 128,962,000Source |
| Assets, CurrentUSD | 3,952,811,000Source | 3,355,424,000Source | 2,985,452,000Source | 4,620,172,000Source | 3,643,699,000Source | 3,172,856,000Source | 3,268,258,000Source | 2,988,607,000Source | 4,050,662,000Source | 3,295,285,000Source | 2,982,697,000Source | 2,692,247,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 188,036,000Source | 145,350,000Source | 157,958,000Source | 302,176,000Source | 147,314,000Source | 154,745,000Source | 152,420,000Source | 201,960,000Source | 281,892,000Source | 116,964,000Source | 126,382,000Source | 132,916,000Source |
| Operating Lease, Right-of-Use AssetUSD | 191,390,000Source | 196,408,000Source | 203,485,000Source | 183,359,000Source | 192,401,000Source | 198,303,000Source | 197,233,000Source | 195,468,000Source | 194,916,000Source | 191,148,000Source | 199,732,000Source | 215,136,000Source |
| Other Assets, NoncurrentUSD | 55,835,000Source | 77,618,000Source | 75,155,000Source | 65,132,000Source | 57,172,000Source | 71,925,000Source | 73,820,000Source | 67,461,000Source | 59,461,000Source | 65,310,000Source | 72,003,000Source | 66,092,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 4,617,768,000Source | 4,172,685,000Source | 4,004,939,000Source | 4,204,651,000Source | 4,315,428,000Source | 4,012,701,000Source | 4,098,376,000Source | 4,043,658,000Source | 4,177,155,000Source | 4,172,895,000Source | 4,050,524,000Source | 3,704,582,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | 0Source |
| Common Stock, Value, IssuedUSD | 1,318,000Source | 1,289,000Source | 1,255,000Source | 1,337,000Source | 1,310,000Source | 1,281,000Source | 1,303,000Source | 1,265,000Source | 1,324,000Source | 1,293,000Source | — | 1,240,000Source |
| Retained Earnings (Accumulated Deficit)USD | -7,160,420,000Source | -7,203,985,000Source | -6,871,721,000Source | -6,332,039,000Source | -7,411,504,000Source | -7,092,415,000Source | -7,345,227,000Source | -7,075,526,000Source | -6,702,524,000Source | -7,287,748,000Source | -7,009,591,000Source | -6,569,349,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -21,775,000Source | -24,826,000Source | -32,339,000Source | -32,138,000Source | -29,952,000Source | -34,637,000Source | -37,517,000Source | -26,988,000Source | -20,097,000Source | -34,518,000Source | -23,375,000Source | -44,654,000Source |
| Stockholders' Equity Attributable to ParentUSD | 233,894,000Source | 32,354,000Source | -165,866,000Source | 1,354,118,000Source | 555,345,000Source | -3,067,000Source | 115,435,000Source | -219,272,000Source | 789,176,000Source | 67,088,000Source | -220,644,000Source | -158,223,000Source |
| Additional Paid in Capital, Common StockUSD | 7,414,771,000Source | 7,259,876,000Source | 6,736,939,000Source | 7,716,958,000Source | 7,690,737,000Source | 7,122,704,000Source | 7,496,876,000Source | 6,881,977,000Source | 7,510,473,000Source | 7,388,061,000Source | 6,811,063,000Source | 6,454,540,000Source |
| Liabilities and EquityUSD | 4,851,662,000Source | 4,205,039,000Source | 3,839,073,000Source | 5,558,769,000Source | 4,566,019,000Source | 4,009,634,000Source | 4,213,811,000Source | 3,824,386,000Source | 4,966,331,000Source | 4,239,983,000Source | 3,829,880,000Source | 3,546,359,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 1,555,477,000Source | 1,220,663,000Source | 949,785,000Source | 1,512,513,000Source | 1,300,847,000Source | 1,055,251,000Source | 1,075,623,000Source | 941,709,000Source | 1,466,349,000Source | 1,186,272,000Source | 967,786,000Source | 767,915,000Source |
| Operating Lease, Liability, CurrentUSD | 44,755,000Source | 42,144,000Source | 41,516,000Source | 45,933,000Source | 46,097,000Source | 41,656,000Source | 46,011,000Source | 41,672,000Source | 45,518,000Source | 41,886,000Source | 41,510,000Source | 41,967,000Source |
| Accounts Payable, CurrentUSD | 117,591,000Source | 70,805,000Source | 73,840,000Source | 108,016,000Source | 102,393,000Source | 73,980,000Source | 97,399,000Source | 78,148,000Source | 115,721,000Source | 88,415,000Source | 55,519,000Source | 98,094,000Source |
| Operating Lease, Liability, NoncurrentUSD | 223,421,000Source | 236,030,000Source | 247,711,000Source | 210,495,000Source | 224,445,000Source | 239,352,000Source | 230,061,000Source | 237,829,000Source | 225,087,000Source | 229,541,000Source | 243,101,000Source | 261,339,000Source |
| Other Liabilities, NoncurrentUSD | 9,769,000Source | 357,477,000Source | 280,734,000Source | 9,152,000Source | 10,932,000Source | 350,428,000Source | 5,871,000Source | 319,990,000Source | 7,594,000Source | 398,108,000Source | 308,438,000Source | 212,580,000Source |
| Additional Financial Items | ||||||||||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | — | — | — | — | — | — | — | — | 102,743,000Source | 99,576,000Source | 32,342,000Source |
| Accrued Liabilities, CurrentUSD | 1,153,648,000Source | 946,168,000Source | 713,094,000Source | 1,095,980,000Source | 918,966,000Source | 808,643,000Source | 704,165,000Source | 698,865,000Source | 1,080,197,000Source | 887,472,000Source | 713,013,000Source | 545,460,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -1,131,156,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | 56,712,000Source | 348,235,000Source | 272,084,000Source | 221,680,000Source | 230,649,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | 7,434,000Source | 359,963,000Source | 86,550,000Source | 87,939,000Source | 45,597,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | -6,215,000Source | -8,474,000Source | -13,590,000Source | -18,367,000Source | 34,136,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | 9,639,000Source | -2,198,000Source | -106,762,000Source | -713,000Source | -1,433,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | — | -118,314,000Source | 524,080,000Source | -8,312,000Source | 104,156,000Source | -541,274,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | 113,769,000Source | 436,329,000Source | -116,840,000Source | -336,350,000Source | 169,354,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | — | — | 2,150,000Source | 117,000Source | 4,438,000Source | 4,694,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 8,970,000Source | 58,697,000Source | 34,277,000Source | 62,211,000Source | 72,059,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 44,084,000Source | -305,190,000Source | 294,159,000Source | 172,131,000Source | 425,753,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | 53,597,000Source | 690,155,000Source | 153,768,000Source | -53,672,000Source | 46,403,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 1,492,802,000Source | 1,102,498,000Source | 1,709,478,000Source | 1,115,861,000Source | 971,193,000Source | 1,022,249,000Source | 1,658,807,000Source | 968,652,000Source | 814,884,000Source | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 66,933,000Source | 218,707,000Source | 67,578,000Source | 32,118,000Source | 45,235,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 2,969,000Source | 15,088,000Source | 14,360,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | 14,058,000Source | 34,936,000Source | -15,239,000Source | 6,391,000Source | -7,430,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 108,211,000Source | 45,804,000Source | 86,625,000Source | 111,680,000Source | 89,288,000Source | 56,712,000Source | 348,235,000Source | 272,084,000Source | 221,680,000Source | 230,649,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 54,800,000Source | 55,100,000Source | 51,600,000Source | 39,100,000Source |
| Depreciation, Amortization and Accretion, NetUSD | — | — | — | — | — | — | — | 14,405,000Source | 55,658,000Source | 56,670,000Source | 54,054,000Source | 44,468,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | — | — | — | — | — | -956,000Source | -2,306,000Source | -3,022,000Source | -16,944,000Source | -33,312,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -42,473,000Source | 0Source | 0Source | -76,586,000Source |
| Income Tax Expense (Benefit)USD | — | — | -12,115,000Source | 2,907,000Source | 13,312,000Source | 30,919,000Source | 5,722,000Source | 15,883,000Source | 9,405,000Source | -99,218,000Source | 6,725,000Source | 4,163,000Source |
| Induced Conversion of Convertible Debt ExpenseUSD | — | — | 39,146,000Source | 0Source | — | — | — | — | 42,473,000Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 44,398,000Source | 34,376,000Source | 82,051,000Source | 61,456,000Source | 33,258,000Source | 38,646,000Source | 252,627,000Source | 141,858,000Source | — | — |
| Investment Income, InterestUSD | — | — | 28,681,000Source | 32,146,000Source | 28,143,000Source | 27,486,000Source | 29,182,000Source | 28,673,000Source | 111,470,000Source | 121,992,000Source | 95,561,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 251,084,000Source | -111,570,000Source | 164,494,000Source | -72,228,000Source | -16,889,000Source | -57,479,000Source | 313,747,000Source | -278,157,000Source | -440,242,000Source | -1,131,156,000Source |
| Nonoperating Income (Expense)USD | — | — | -129,013,000Source | -31,758,000Source | -53,635,000Source | -25,110,000Source | -59,781,000Source | -59,673,000Source | -178,426,000Source | -200,490,000Source | -151,342,000Source | -341,921,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 61,600,000Source | 58,600,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -74,150,000Source | -29,528,000Source | 273,000Source | 8,860,000Source | -55,705,000Source | -49,700,000Source | 5,204,000Source | -180,624,000Source | -125,682,000Source | -109,367,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,249,026,000Source | 500,919,000Source | 1,290,948,000Source | 773,689,000Source | 659,825,000Source | 594,189,000Source | 3,713,937,000Source | 2,248,243,000Source | 1,828,292,000Source | 1,037,418,000Source |
| Cost of RevenueUSD | — | — | 197,231,000Source | 81,980,000Source | 298,261,000Source | 142,029,000Source | 67,271,000Source | 70,183,000Source | 677,166,000Source | 306,513,000Source | 268,216,000Source | 140,174,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 322,076,000Source | 220,993,000Source | 347,922,000Source | 323,314,000Source | 248,397,000Source | 239,949,000Source | 1,210,713,000Source | 975,526,000Source | 795,646,000Source | 770,658,000Source |
| Operating Income (Loss)USD | — | — | 367,982,000Source | -76,905,000Source | 231,441,000Source | -16,199,000Source | 48,614,000Source | 18,077,000Source | 501,578,000Source | -176,885,000Source | -282,175,000Source | -785,072,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -74,150,000Source | -29,528,000Source | 273,000Source | 8,860,000Source | -55,705,000Source | -49,700,000Source | 5,204,000Source | -180,624,000Source | -125,682,000Source | -109,367,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 238,969,000Source | -108,663,000Source | 177,806,000Source | -41,309,000Source | -11,167,000Source | -41,596,000Source | 323,152,000Source | -377,375,000Source | -433,517,000Source | -1,126,993,000Source |
| Income Tax Expense (Benefit)USD | — | — | -12,115,000Source | 2,907,000Source | 13,312,000Source | 30,919,000Source | 5,722,000Source | 15,883,000Source | 9,405,000Source | -99,218,000Source | 6,725,000Source | 4,163,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 251,084,000Source | -111,570,000Source | 164,494,000Source | -72,228,000Source | -16,889,000Source | -57,479,000Source | 313,747,000Source | -278,157,000Source | -440,242,000Source | -1,131,156,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 1.91Source | -0.87Source | 1.23Source | -0.55Source | -0.13Source | -0.44Source | 2.39Source | -2.18Source | -3.52Source | -9.3Source |
| Earnings Per Share, DilutedUSD per share | — | — | 1.84Source | -0.87Source | 1.21Source | -0.55Source | -0.13Source | -0.44Source | 2.33Source | -2.18Source | -3.52Source | -9.3Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 131,447,000Source | 128,590,000Source | 133,606,000Source | 130,628,000Source | 126,733,000Source | 129,676,000Source | 131,004,000Source | 127,651,000Source | 124,906,000Source | 121,689,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 137,348,000Source | 128,590,000Source | 138,281,000Source | 130,628,000Source | 126,733,000Source | 129,676,000Source | 134,684,000Source | 127,651,000Source | 124,906,000Source | 121,689,000Source |
| Interest Expense (non-operating)USD | — | — | 44,398,000Source | 34,376,000Source | 82,051,000Source | 61,456,000Source | 33,258,000Source | 38,646,000Source | 252,627,000Source | 141,858,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 881,044,000Source | 577,824,000Source | 1,059,507,000Source | 789,888,000Source | 611,211,000Source | 576,112,000Source | 3,212,359,000Source | 2,425,128,000Source | 2,110,467,000Source | 1,822,490,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 11,603,000Source | 7,544,000Source | 7,438,000Source | 5,596,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 18,300,000Source | -571,926,000Source | -450,311,000Source | -1,148,604,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 121,221,000Source | 155,968,000Source |
| Investment Income, InterestUSD | — | — | 28,681,000Source | 32,146,000Source | 28,143,000Source | 27,486,000Source | 29,182,000Source | 28,673,000Source | 111,470,000Source | 121,992,000Source | 95,561,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -129,013,000Source | -31,758,000Source | -53,635,000Source | -25,110,000Source | -59,781,000Source | -59,673,000Source | -178,426,000Source | -200,490,000Source | -151,342,000Source | -341,921,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 61,600,000Source | 58,600,000Source |
| Research and Development ExpenseUSD | — | — | 358,814,000Source | 270,926,000Source | 413,134,000Source | 323,621,000Source | 294,142,000Source | 265,122,000Source | 1,319,775,000Source | 1,126,232,000Source | 1,004,415,000Source | 883,015,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
d201569dex991.htm · 8-K · 2025-12-11
EX-99.1 2 d201569dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 December 11, 2025 CAMBRIDGE, Mass. - December 11, 2025 - Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with certain holders of its 1.00% Convertible Senior Notes due 2027 (the “Notes”) to repurchase for cash (t…
Read attachment ↗d949176dex41.htm · 8-K · 2025-09-12
EX-4.1 2 d949176dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 Execution Version ALNYLAM PHARMACEUTICALS, INC. AND THE BANK OF NEW YORK MELLON, as Trustee INDENTURE Dated as of September 12, 2025 0.00% Convertible Senior Notes due 2028 TABLE OF CONTENTS PAGE ARTICLE 1 Definitions Section 1.01. …
Read attachment ↗d72540dex991.htm · 8-K · 2025-09-10
EX-99.1 2 d72540dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes CAMBRIDGE, Mass. - September 8, 2025 - Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursu…
Read attachment ↗d72540dex992.htm · 8-K · 2025-09-10
EX-99.2 3 d72540dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes CAMBRIDGE, Mass. - September 9, 2025 - Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028 (the “notes”) to persons reasonably believed to be qual…
Read attachment ↗